Antibodies to AChRs in seronegative myasthenia gravis

Antibodies to AChRs in seronegative myasthenia gravis

Detalles Bibliográficos
Main Authors:	Leite, M, Cossins, J, Beeson, D, Willcox, N, Vincent, A
Formato:	Conference item
Publicado:	2006

Títulos similares

Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures.
por: Farrugia, M, et al.
Publicado: (2007)

Antibodies to clustered acetylcholine receptor and thymic changes in seronegative myasthenia gravis
por: Leite, M, et al.
Publicado: (2007)

Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis.
por: Maclennan, C, et al.
Publicado: (2008)

IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
por: Leite, M, et al.
Publicado: (2008)

Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
por: Deymeer, F, et al.
Publicado: (2007)

Myasthenia gravis seronegative for acetylcholine receptor antibodies.
por: Vincent, A, et al.
Publicado: (2008)

Myasthenia gravis in a woman with congenital AChR deficiency due to epsilon-subunit mutations.
por: Croxen, R, et al.
Publicado: (2002)

AChR phosphorylation and indirect inhibition of AChR function in seronegative MG.
por: Plested, C, et al.
Publicado: (2002)

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient
por: Saxena, A, et al.
Publicado: (2017)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.
por: Vuslat Yilmaz, et al.
Publicado: (2015-01-01)

A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis
por: Yu Cai, et al.
Publicado: (2021-07-01)

IgG subclasses of disease-specific antibodies and complement activation in-vitro in seronegative myasthenia gravis and neuromyelitis optica
por: Jacob, S, et al.
Publicado: (2008)

Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis
por: Lee, J, et al.
Publicado: (2016)

Oral Microbiota Profile in a Group of Anti-AChR Antibody–Positive Myasthenia Gravis Patients
por: Chao Huang, et al.
Publicado: (2022-07-01)

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.
por: McConville, J, et al.
Publicado: (2004)

Seronegative myasthenia gravis.
por: Vincent, A, et al.
Publicado: (2004)

SERONEGATIVE MYASTHENIA GRAVIS-CLINICAL/SEROLOGICAL ASPECTS
por: Huda, S, et al.
Publicado: (2014)

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
por: Rui Zhao, et al.
Publicado: (2021-06-01)

Clinical outcomes in AchR antibody-positive myasthenia gravis: Where does rituximab stand in the current times?
por: Megha Chetan Dhamne
Publicado: (2023-01-01)

Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.
por: Gregory Kordas, et al.
Publicado: (2014-01-01)

The clinical outcome in AChR-positive generalized myasthenia gravis: A retrospective observational study
por: Pawan T Ojha, et al.
Publicado: (2023-01-01)

Detection of musk antibodies in seronegative myasthenia gravis using human musk as antigen
por: McConville, J, et al.
Publicado: (2002)

Consensus recommendation for the treatment of generalised Myasthenia Gravis with anti-acetylcholine receptor antibodies (gMG AChR+) in Spain
por: Elena Cortés-Vicente, et al.
Publicado: (2025-01-01)

MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters
por: Koneczny, I, et al.
Publicado: (2013)

MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
por: Koneczny, I, et al.
Publicado: (2013)

Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort
por: Antonino Lupica, et al.
Publicado: (2022-04-01)

Correction: Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients.
por: PLOS ONE Staff
Publicado: (2015-01-01)

Correction: direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.
por: PLOS ONE Staff
Publicado: (2015-01-01)

Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody
por: Yuping Chen, et al.
Publicado: (2022-05-01)

Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.
por: Vincent, A, et al.
Publicado: (2003)

MuSK antibody-positive, seronegative myasthenia gravis in Korea.
por: Lee, J, et al.
Publicado: (2006)

MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
por: Inga Koneczny, et al.
Publicado: (2013-01-01)

Correlation between polymorphisms in the AChR gamma and delta subunit promoters and clinical phenotype in AChR deficiency patients
por: Bonifati, D, et al.
Publicado: (2004)

Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
por: Eleonora Lekova, et al.
Publicado: (2022-09-01)

A mouse model of AChR deficiency syndrome with a phenotype reflecting the human condition.
por: Cossins, J, et al.
Publicado: (2004)

Autoantibody of NRIP, a novel AChR‐interacting protein, plays a detrimental role in myasthenia gravis
por: Li‐Kai Tsai, et al.
Publicado: (2021-06-01)

Juvenile Generalized Myasthenia Gravis With AChR and MuSK Antibody Double Positivity: A Case Report With a Review of the Literature
por: XiuShan Ge, et al.
Publicado: (2022-05-01)

FoxP3− Tr1 Cell in Generalized Myasthenia Gravis and Its Relationship With the Anti-AChR Antibody and Immunomodulatory Cytokines
por: Huanyu Meng, et al.
Publicado: (2021-12-01)

Antibodies identified by cell-based assays in myasthenia gravis and associated diseases.
por: Vincent, A, et al.
Publicado: (2012)

Antibodies affecting ion channel function in acquired neuromyotonia, in seropositive and seronegative myasthenia gravis, and in antibody-mediated arthrogryposis multiplex congenita.
por: Vincent, A, et al.
Publicado: (1998)